- Home
- SENEB vs SCLXW Comparison
SENEB vs SCLXW Comparison
Compare SENEB & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEB
- SCLXW
- Stock Information
- Founded
- SENEB 1949
- SCLXW N/A
- Country
- SENEB United States
- SCLXW United States
- Employees
- SENEB N/A
- SCLXW 31
- Industry
- SENEB Packaged Foods
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- SENEB Consumer Staples
- SCLXW Health Care
- Exchange
- SENEB Nasdaq
- SCLXW Nasdaq
- Market Cap
- SENEB 813.0M
- SCLXW N/A
- IPO Year
- SENEB N/A
- SCLXW N/A
- Fundamental
- Price
- SENEB $121.50
- SCLXW $0.22
- Analyst Decision
- SENEB
- SCLXW
- Analyst Count
- SENEB 0
- SCLXW 0
- Target Price
- SENEB N/A
- SCLXW N/A
- AVG Volume (30 Days)
- SENEB 772.0
- SCLXW 4.0K
- Earning Date
- SENEB 11-05-2025
- SCLXW 03-07-2025
- Dividend Yield
- SENEB N/A
- SCLXW N/A
- EPS Growth
- SENEB 47.79
- SCLXW N/A
- EPS
- SENEB 8.61
- SCLXW N/A
- Revenue
- SENEB $1,606,175,000.00
- SCLXW $55,152,000.00
- Revenue This Year
- SENEB N/A
- SCLXW N/A
- Revenue Next Year
- SENEB N/A
- SCLXW N/A
- P/E Ratio
- SENEB $14.04
- SCLXW N/A
- Revenue Growth
- SENEB 8.33
- SCLXW 22.02
- 52 Week Low
- SENEB $70.50
- SCLXW $0.18
- 52 Week High
- SENEB $126.05
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- SENEB 72.26
- SCLXW 46.20
- Support Level
- SENEB $110.57
- SCLXW $0.21
- Resistance Level
- SENEB $112.30
- SCLXW $0.24
- Average True Range (ATR)
- SENEB 0.35
- SCLXW 0.05
- MACD
- SENEB 0.29
- SCLXW -0.00
- Stochastic Oscillator
- SENEB 100.00
- SCLXW 18.00
About SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.